Catalent Experts Exhibit and Present at BIO and Interphex 2013
SOMERSET, NJ, April 19, 2013 — Catalent Pharma Solutions, a leading provider of drug and biologic development services, delivery technologies and supply solutions, will be exhibiting and speaking at two of North America’s largest annual pharma events next week, and will be located on Booth 4571 Hall C at the BIO International Convention (April 22-25, 2013, McCormick Place, Chicago, IL) and Booth 3816 at INTERPHEX (April 23-25, Javits Center, New York).
At BIO, Dr. Greg Bleck, R&D Platform Director, Biologics, will present “Optimized Solutions for Better Biologic Treatments,” looking at current Bio trends and solutions to create better treatments utilizing protein enhancement technologies, advanced cell line engineering systems and single-use manufacturing innovations, including the challenges and opportunities of converting to a new fully single-use facility. Dr. Bleck’s presentation will take place on Wednesday, April 24 from 10:30 – 10:55AM in the BioProcess Theater, within the BioProcess Zone on the BIO Exhibit Hall Floor.
Additionally on Wednesday 24th, from 2 PM- 2.45 PM in Room S106A, Catalent will hold a Press Briefing, discussing “Bio Trends: Better Proteins and Single-Use Manufacturing.”
The panel of speakers will discuss current trends within the Biopharmaceutical industry regarding optimized solutions to create better proteins utilizing protein enhancement technologies, advanced cell line engineering systems and single-use manufacturing trends going forward. Catalent will highlight decisions to convert to its new fully single-use facility in Madison, set to open at an official ceremony after the show closes on Friday 26th April.
Dr. Gregory Bleck joined Catalent in 1998 as Director of Molecular Biology & Transgenics. He has a broad background in molecular biology, mammalian gene expression, cell culture and transgenic animals with 13 years experience with the organization. Greg holds a Bachelor’s degree in Dairy Science and has a Doctorate in Endocrinology-Reproductive Physiology from University of Wisconsin-Madison. He performed postdoctoral work at the University of Illinois-Urbana working in the areas of gene regulation and expression. Greg has published over 55 research papers, co-authored three book chapters and is inventor or co-inventor on 10 patents.
Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products. With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 9,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com.